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ABSTRACT 
For more than a decade, the integration of human and environmental risk assessment 
(RA) has become an attractive vision. At the same time, existing European regulations of 
chemical substances such as REACH (EC Regulation No. 1907/2006), the Plant Protection 
Products Regulation (EC regulation 1107/2009) and Biocide Regulation (EC Regulation 
528/2012) continue to ask for sector-specific RAs, each of which have their individual 
information requirements regarding exposure and hazard data, and also use different 
methodologies for the ultimate risk quantification. In response to this difference between the 
vision for integration and the current scientific and regulatory practice, the present paper 
outlines five medium-term opportunities for integrating human and environmental RA, fol-
lowed by detailed discussions of the associated major components and their state of the art. 
Current hazard assessment approaches are analyzed in terms of data availability and quality, 
and covering non-test tools, the integrated testing strategy (ITS) approach, the adverse out-
come pathway (AOP) concept, methods for assessing uncertainty, and the issue of explicitly 
treating mixture toxicity. With respect to exposure, opportunities for integrating exposure 
assessment are discussed, taking into account the uncertainty, standardization and validation 
of exposure modelling as well as the availability of exposure data. A further focus is on ways 
to complement RA by a socio-economic assessment (SEA) in order to better inform about risk 
management options. In this way, the present analysis, developed as part of the EU FP7 
project HEROIC, may contribute to paving the way for integrating, where useful and possible, 
human and environmental RA in a manner suitable for its coupling with SEA. 
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1. Introduction.  
 
Current risk assessment (RA) policies, processes and practices have been established 
through extensive cumulative experience of scientists from many disciplines and in different 
countries over decades, resulting in national and international regulations for a wide range of 
stressors. Nevertheless, RA is facing increasing challenges, in particular with regard to 
increasing scientific complexity, public perception and resourcing.  
On the one hand, the categories and number of substances for which a human and/or 
environmental RA is required will continue to increase substantially due to revised legislation 
(e.g. REACH: Registration, Evaluation, Authorisation and Restriction of Chemical 
substances ; more complete ecological risk assessment is expected for pharmaceuticals in the 
next few years). The need to assess the impacts of multiple stressors and the toxicity of 
mixtures adds additional complexity. On the other hand, non-scientific considerations such as 
budget restrictions or political and public pressure to reduce the number of animal tests for the 
purpose of safety assessments also drive further developments in RA.  
Taken together, these developments create the need for better exploiting all currently 
existing data, and it is assumed that a more integrated approach to RA is part of the solution. 
In theory, the potential benefits of Integrated Risk Assessment (IRA) have been recognized 
for more than a decade. Several projects have been carried out including a joint WHO-
IPCS/US-EPA project (WHO, 2001) and a range of EU projects (for instance INTARESE 
(http://www.intarese.org/), HEIMTSA (http://www.heimtsa.eu/), 2-FUN (http://www.2-
fun.org/), NOMIRACLE (nomiracle.jrc.ec.europa.eu/)) have already addressed integrated risk 
assessment. However, the impact of those initiatives on the development of IRA-approaches 
has been limited so far, and today no explicit legal mandates for IRA exist. Therefore, there is 
not yet consensus among experts about the scale of implementation achieved so far. This is 
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partly because there is no harmonized definition and understanding of what IRA means in 
practice.  
As a step towards a common understanding of integrated risk assessment, and to 
assess how risk analysis and socio-economic analysis can benefit from each other, this paper 
reviews perspectives in integrated hazard and exposure assessment. The work presented here 
is derived from reviews performed by partners of the HEROIC project (Health and 
Environmental Risks: Organisation, Integration and Cross-fertilisation of Scientific 
Knowledge, FP7, Grant Agreement no. 282896), from discussions during the first expert 
meeting within the HEROIC project, organized at INERIS (Verneuil-en-Halatte, FRANCE) 
the 12
th
 and 13
th
 of April 2012, and from a meeting with the Scientific Advisory Board of 
HEROIC on 21 September 2012 in Basel, Switzerland. The HEROIC project was established 
to promote strengthening of the interfaces between human and environmental endpoints 
within RA procedures, thus paving the way towards an integrated approach where the 
exploitation of mechanistic information across human and environmental toxicology becomes 
a focal theme. Below, the HEROIC view of the opportunities for integrated risk assessment is 
outlined, followed by more detailed discussions of current developments in the areas of 
exposure, hazard and risk assessment. Particular emphasis is placed on integrated testing stra-
tegies with explicit consideration of mixture toxicity and approaches to augment RA by a 
socio-economic assessment. 
With the implementation of REACH on June 1, 2007, the concept of integrated testing 
strategies (Ahlers et al., 2008; Bradbury et al., 2004; Combes and Balls, 2005; OSIRIS, 2011) 
became an official part of the European-wide regulation of industrial chemicals. As outlined 
in more detail below, the ITS approach builds on the combined information content extract-
able from non-test and test data including information from non-standard (non-guideline) 
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sources, confining the additional generation of animal-based data to the minimum required for 
completing the assessment of interest. 
While the ITS concept mainly focuses on integrating different types of information for 
assessing the human or environmental hazard potential of chemical substances, an extension 
of this approach to exposure assessment and to eventually assessing human and 
environmental risk is the subject of the integrated RA framework. Within HEROIC, the 
following five medium-term opportunities for RA integration have been identified: 
 Employ the mode of action (MOA), or eventually the adverse outcome pathway (see 
below) as a trigger and criterion for the mutual exploitation of environmental and 
human toxicology data. 
 Explore the applicability of existing weight-of-evidence (WoE) schemes for integrat-
ing environmental toxicity data into human health assessments and vice versa, 
considering appropriate means for assessing the level of confidence (or level of 
uncertainty) of the individual data as well as of their combined content. 
 Provide a framework for merging risks associated with individual exposure routes into 
an overall risk reflecting the combined exposure. 
 Include an explicit consideration of mixture toxicity effects into human and 
environmental risk assessment 
 Augment the risk assessment process by a socio-economic analysis targeted to inform 
about the pros and cons of possible risk management options. 
At present, these five issues are considered as a roadmap of opportunities toward 
building integrated RA procedures, to which HEROIC will contribute through scientific 
networking activities on a European scale and across academia, business and regulatory 
authorities. 
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2. Perspectives on integrated hazard assessment contributing to integrated risk 
assessment  
Integrated hazard assessment relates to the possibility of combining information 
content from non-test and test data including information from non-standard (non-guideline) 
sources or from species different from the targeted one (in particular when integrating 
environmental toxicity data into human health assessments and vice versa). The success of 
such integrated hazard assessment relies on four conditions. First the amount of available data 
should be sufficient, which means that availability of hazard data should be enhanced. 
Second, a framework is needed which must be able to integrate different information for a 
given endpoint. This is what is expected from the Adverse Outcome Pathways (AOPs, Ankley 
et al., 2010). Third, hazard assessors should have appropriate tools, in particular with regard 
to modeling, for the integration and the extrapolation. Fourth, managing different sources of 
data (measured, extrapolated, non-test data) requires the development of methods to assess the 
confidence level of data, which would contribute to building relevant weight-of-evidence 
(WoE) approaches.  
 
2.1. Improving data availability for risk assessors 
 
The benefit of sharing toxicity and exposure data and making them available is largely 
recognized. However, most of the data used in risk assessment for substances and products 
remain confidential, in particular due to intellectual property issues.  
There are many reasons for the lack of publicly available data. They may only be 
available as paper copies not suitable for immediate electronic storage or sharing. Moreover, 
there could be no suitable platform to share data (cf. inventory with separate databases), or 
there is little or no compatibility of databases, data structure or descriptors. Significant efforts 
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are now being undertaken to at least partially answer the need to share information and 
develop common templates and descriptors. Examples include TOXNET 
(http://toxnet.nlm.nih.gov/), e-Chem portal (www.echemportal.org/), and IUCLID (iuclid.eu/). 
The OECD QSAR Toolbox also proposes a way to link databases together. The limitation is 
that so far only a part of the information is accessible via these formats, and only information 
developed within a regulatory context is included. Pharmaceuticals, plant protection products 
(PPP) and biocides are not included in shareable formats.  
A practical solution to overcome the issue of data confidentiality has been proposed in the EU 
IMI project “Integrating bioinformatics and chemoinformatics approaches for the 
development of expert systems allowing the in silico prediction of toxicities” (eTOX) which 
includes academic institutions, small and medium-sized enterprises (SMEs), and large 
pharmaceutical companies (Briggs et al., 2012). The companies participating in the project 
consortium share confidential data to build predictive tools or perform compound 
comparisons, but the access is restricted to one of the SMEs, called “honest broker”. Data 
confidentiality is not only limited to private companies and registration. Distributed Structure-
Searchable Toxicity (DSSTox) Database Network (www.epa.gov/ncct/dsstox/) is a project 
of EPA's National Center for Computational Toxicology, which aims to build a public toxicity 
database for improved structure-activity and predictive toxicology capabilities.  Among the 
reasons why a potential author may consider publishing a database on DSSTox are increased 
recognition for authorship and expertise relative to a toxicity database; increased visibility and 
use of the database by a wide range of users and scientific disciplines; ability to merge the 
database with many other toxicity databases in structure-searchable format; potential for 
collaborations and user feedback. In order to foster data sharing further, it could be useful to 
create a peer-review journal dedicated to publishing data that can be shared. Any use of data 
published in this journal would require the citation of the associated article. 
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2.2. Non-test tools to extrapolate in hazard assessment  
 
Non-test methods can permit the extrapolation of available toxicological information, 
between chemicals, between species and between different levels of biological organization, 
and support integrated risk assessment by generating additional information. 
QSAR models and read-across can be used in order to extrapolate data from one 
chemical to another. Read-across is based on experimental data and expert judgment, which is 
different from QSAR models, which propose a regression-based relationship between the 
values of relevant descriptors and the toxicological response. Read-across requires the 
assessment of chemical similarity. The latter can be defined in a number of ways, and in fact 
can be understood as covering different components (e.g. structural similarity, presence of 
certain structural alerts, physicochemical profile), the selection of which depends on the target 
property of interest. Typically, some method of assessing structural similarity (e.g. finding 
structural analogs or employing atom-centered fragments (Kühne et al., 2009)) forms the 
starting point. Within the toxicological context further issues such as bioavailability 
(characterized through a certain physicochemical profile (Dimitrov et al., 2005)), presumed 
mechanism and mode of action, potential involvement of metabolic conversion leading to 
toxification, detoxification or more efficient elimination can be invoked. An analysis of the 
REACH dossiers submitted to ECHA during the first registration period between 1 June 2008 
and 28 February 2011 (high production volume chemicals and substances of very high 
concern) revealed that among the non-test methods, read-across has by far had largest use, 
while QSAR-based information apparently played only a minor role (Spielmann et al., 2011). 
At the same time, current practice indicates that there is a lack of experience in regulatory 
contexts with read-across despite the fact that the general principles of this predictive 
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approach are already covered by existing guidelines (OECD, 2007; OECD, 2009). Within 
these documents it is acknowledged that by means of a learning-by-doing approach, the 
experience gained in application of read-across will lead to further improvements and changes 
of existing guidance documents. Indeed, the majority of the examples that the available 
documents provide are mainly focused on toxicological endpoints that are governed by rather 
well understood mechanisms for which there are well populated databases (e.g. skin 
sensitization, Ames genotoxicity, aquatic toxicity). In this respect the ECETOC technical 
report on read-across (ECETOC, 2012) provides a new analysis on the impact of predictions 
based on the analogue approach by highlighting two facts: data on toxicokinetics can be a key 
piece of evidence when substantiating a read-across approach and these data can be collected 
during standard toxicological studies with very limited consequences on animal welfare. 
Moreover, this report also pointed out that, at the current time, read-across is limited to small 
chemical categories in order to counterbalance lack of mechanistic knowledge about certain 
endpoints. According to the ECETOC report this limitation will be removed in the next future 
thanks to programs such as Toxicity testing in the 21
st
 century (Bhattacharya et al., 2011).  
Integration of data obtained for species or biological levels of organization different 
from the target requires the assessment of the dose response for both toxicokinetics (exposure 
concentration at local or systemic level for a given dose) and toxicodynamics (local or 
systemic dose-response depending on the endpoint considered). Comparative toxicokinetics is 
based on physiologically-based toxicokinetics (PBTK) models. A PBTK model consists of a 
series of mathematical equations which, based on the specific physiology of an organism and 
on the biophysical properties of a substance, are able to describe the absorption, distribution, 
metabolism and elimination (ADME) of the compound within this organism. Inter-species 
extrapolation is by far the most common and the most documented PBTK usage in 
pharmacokinetics (Nestorov, 2003). The scaled species-specific information is most often 
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related to physiological parameters, even if some compound specific information, obtained in 
vitro for instance, can be used. In terms of toxicodynamics, a way forward could be to 
promote using mechanistic information available for one sector (e.g. endocrine disruption in 
aquatic toxicology) to another sector (e.g. human health), and thus more generally to exploit 
toxicological information across traditional boundaries. AOP approaches should help in 
achieving the goal. Indeed, interspecies extrapolation would be facilitated through the 
identification of common key receptors or the use of comparative genomics that would 
indicate the plausibility of common key events (OECD, 2011). 
There are only a few examples for which PBTK models were used to extrapolate in 
vitro response to in vivo hazard assessment (e.g. Punt et al., 2011). In general, the predictions 
over-estimated the toxicity, which could be both due to overestimation of the effects in the in 
vitro systems and uncertainty on the toxicokinetics parameters. Thus, there are improvements 
to be made both in the experimental design and in the accurate calibration of toxicokinetics 
models. As stated by Punt et al. (2011), more examples that provide proof of principle for 
deriving in vivo dose–response curves based on in vitro assays and PBK modeling techniques 
will be necessary for integrated hazard assessment. 
 
2.3. Integrated Testing Strategies 
   
The introduction of the concept of Integrated Testing Strategies (ITS) in the preparation phase 
of REACH constituted a paradigm shift regarding the use of alternative methods for the 
hazard assessment of chemical substances: The original 3R idea of one-to-one replacements 
of animal tests by in vitro tools was converted into the broader concept of replacing one 
animal test by the combined use of several non-animal methods. Respective ITS methods and 
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guidance have been developed in the EU-funded project OSIRIS for both human and 
environmental endpoints (OSIRIS, 2011). 
In an ITS, both non-test and test data may be included. In addition to methods providing data 
for the physicochemical properties and the human or environmental toxicity endpoint of 
interest, information theory tools such as (qualitative or quantitative) weight of evidence and 
consensus modelling can be employed. This will help to unravel the combined information 
content, and to possibly augment the resulting evaluation with a certain level of probability. 
Typical ITS components for providing non-test and test data can be grouped into three 
classes, with in vivo methods being understood as being last resort: 
Non-test (in silico) methods 
• Analysis of existing test data 
• Read-across 
• Chemical categories 
• Structural alerts 
• QSAR (quantitative and qualitative structure-activity relationships) 
• Exposure modelling 
• TTC (thresholds of toxicological concern) 
Non-animal tests 
• In chemico (chemoassays) 
• In vitro (bioassays) 
• Omics (transcriptomics, proteomics, metabolomics) 
• Exposure monitoring 
In vivo methods 
• Lower-tier tests (short-term, single organisms) 
• Higher-tier tests (long-term, population, community) 
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Regarding the prediction of physicochemical properties from chemical structure, the reader is 
referred to an earlier review (Schüürmann et al., 2007), keeping in mind that some of these 
properties also trigger the need for animal testing (e.g. bioconcentration testing becomes 
relevant if the logarithmic octanol/water partition coefficient, log Kow, is above 3, because this 
indicates that the substance may bioaccumulate to a significant degree (ECHA, 2012)). Note, 
however, that seemingly minor issues such as wrong tautomers – a problem sometimes 
overlooked in existing chemical inventories – may result in severe prediction errors 
(Thalheim et al., 2010), which is also a concern when exceeding the QSAR application 
domain (Dimitrov et al., 2005; Kühne et al., 2009). 
One of the main challenge in ITS is to provide information when experimental data are 
missing. Examples of in silico ITS components for human and environmental toxicology 
include structural alerts for the predictive identification of high-concern compounds (Benigni 
and Bossa 2011; Mekenyan et al., 2010; von der Ohe et al., 2005), and a first fully 
computerized read-across approach for predicting the acute fish toxicity of organic 
compounds (Schüürmann et al., 2011). Within more narrow mechanistic domains such as 
Michael-acceptor electrophiles, α-alkyl nitrosamine pro-electrophiles and primary aromatic 
amines, in silico tools employing computational chemistry may inform about reactivity-driven 
toxicity (Mulliner et al., 2011, Wondrousch et al., 2010) as well as about predominant 
metabolic activation pathways (Ji and Schüürmann, 2012, 2013). 
Reactive toxicity can also be sensed experimentally through chemoassays, focusing on 
covalent binding either to proteins or to the DNA (Böhme et al., 2010, Lalko et al., 2011, 
Schwöbel et al., 2011, Thaens et al., 2012). In this context, a further non-animal approach is 
given by aquatic bioassays and their potential for identifying reactive-toxic compounds 
through their excess toxicity as opposed to baseline narcosis (Blaschke et al. 2012, Schramm 
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et al., 2011), thus supporting the identification of structural alerts as the basis for the 
development and extension of respective in silico models. 
For a given endpoint and substance of interest, the ITS procedure starts by collecting all 
potentially relevant data. Besides data generated according to the respective guidelines (e.g. 
OECD guidelines), also non-standard data may be taken into account, keeping in mind that in 
the case of toxicological or ecotoxicological endpoints, additional in vivo testing should be 
considered only as a last resort. Subsequently, the collected data need to be assessed with 
regard to their reliability and relevance for the intended purpose, which in our context would 
be risk assessment, but could also be classification and labelling. The final step is a weight-of-
evidence (WoE) evaluation (Weed, 2005) of the combined information content, taking into 
account methods to assess the overall level of uncertainty or level of confidence, and 
considering opportunities for consensus modelling. Respective computerized ITS schemes for 
the human endpoints skin sensitization, mutagenicity and carcinogenicity (Buist et al., 2013), 
repeated-dose toxicity (Tluczkiewicz et al., 2013), and for the environmental endpoints 
aquatic toxicity and bioconcentration are available through the free-of-charge OSIRIS web-
tool (OSIRIS, 2011). 
Regarding the RA context, the ITS approach focuses on integrating the hazard assessment 
procedure, while the still broader scope of an integrated RA is understood to include methods 
for addressing cumulative exposure and mixture toxicity (see below) and possibly further 
levels of integration. 
 
2.4. Adverse Outcome Pathways (AOPs) 
 
In response to apparent differences in understanding of the terms mode of action 
(MOA) and mechanism of action, Ankley et al. (2010) introduced the term adverse outcome 
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pathway (AOP) as a unifying concept. While the term MOA was originally introduced as a 
sequence of key events at the biochemical or physiological level leading to the toxicological 
response, the mechanism of action can be understood as a comprehensive description of all 
relevant steps from the molecular initiating event to the toxicity at the phenomenological level 
(Ankley et al., 2010; Carmiachael et al., 2011; ECETOC, 2006, 2007). 
In practice, however, a MOA is often confined to a selected response at the bioche-
mical or physiological level (e.g. oxidative uncoupling) or simply refers to the molecular 
initiating event (e.g. DNA-reactive mode of mutagenicity), whilst a mechanism of action typi-
cally refers to a selected series of molecular-level steps before the final outcome (e.g. dioxin 
toxicity: association with the Ah receptor in the cytosol, translocation to the nucleus, associa-
tion with the Ah receptor nuclear translocator (ARNT), binding at DNA inducing expression 
of mRNA and protein synthesis). 
In this context, the AOP was defined as a conceptual construct that represents the 
sequence of events from the molecular initiating event to the adverse outcome at the level of 
interest (Ankley et al., 2010). AOPs span multiple levels of biological organization (OECD, 
2012). In Figure 1, the AOP approach is illustrated by a sequence of major steps involved in 
the development of a toxicological response. 
 
2.5. Accounting for uncertainty in integrated hazard assessment 
 
Integrative methods such as those presented previously allow the use of all possible 
sources of information and data by using measured or extrapolated data, or data generated 
through modeling approaches. As the nature of these data is very diverse, the integration or 
weightings of the different information should account for the level of confidence or certainty 
of the data relative to the ultimate prediction of an adverse effect. If predictive uncertainty for 
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point estimates were derived in the form of probabilistic distributions for in vivo tests, in vitro 
tests and non-test methods, the relevance of ITS to support decisions would be improved 
(Jaworska et al., 2010, Péry et al., 2010). 
Statistical methods are available or under development to assess the uncertainty of 
toxicological and ecotoxicological data, QSAR predictions and reference standard tests. 
Indeed, it is important to note that even data from reference tests have an inherent uncertainty 
(Péry et al., 2010). For instance, Janer et al. (2007) showed that the difference between two 
NOAELs for the same subchronic study performed for the same chemical could be up to a 
factor around 10. The calculation of a confidence interval for a test method is almost 
straightforward now. For instance, the confidence in BMDx (benchmark dose corresponding 
to x% of effect) can be calculated through existing software (Davis et al., 2011). In particular, 
the estimation of a BMD 95% lower bound confidence limit (BMDL) permits accounting for 
study quality (i.e. sample size).  
The uncertainty in predictions of non-test methods such as QSAR models should be 
verified, ideally with an external test set (i.e. a set of chemicals that was not used in the model 
development), provided that the latter covers the relevant chemical domain properly. In case a 
sufficient number of new data for compounds with a sufficient variation in chemical structure 
are not available, cross-validation, bootstrapping or re-sampling offer useful alternatives. In 
any case, the uncertainty associated with a QSAR prediction cannot be expected to be lower 
than the uncertainty of the data on which the QSAR model is based. Recent developments in 
QSAR models now permit better estimates of the uncertainty in the prediction. They consider 
the model itself as well as the distance between the query molecule and the applicability 
domain for which the model is valid (Pery et al., 2009; Tebby and Mombelli, 2012). Since the 
applicability domain is fuzzy to some degree, a methodology based on atom-centered 
fragments (ACFs) has been developed to identify intermediate levels of belonging (Kühne et 
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al. 2009). Application of this approach to existing QSAR models that were confronted with 
data published after their development demonstrated an external performance similar to the 
original calibration performance only for the ACF-based category “inside”, a moderate but 
significant increase in the average prediction error for compounds “borderline inside”, and 
further stepwise decreases in the prediction performance for compounds of the “borderline 
outside” and “outside” categories. It must also be noted that even inside the applicability 
domain, predictive uncertainty can vary especially in case of chemicals that are not uniformly 
distributed in the chemical space defined by the selected physicochemical descriptors (Schultz 
et al., 2007). 
 
3. Perspectives in integrated exposure assessment  
 
3.1. What is integrated exposure assessment? 
 
By definition, exposure assessment establishes the link from (intentional or 
unintentional) emissions of chemicals into the environment to exposure of biological targets. 
These latter can be considered at different scales: ecosystems, communities, populations, 
whole organisms, organs, tissues, cells. Exposure assessment is, by essence, integrated, 
because it has to account for all the interacting compartments and physico-chemical 
phenomena involved in the fate of the chemical under investigation. In the Emission-to-target 
chain several steps can be defined (Figure 2). First, environmental transport and fate describe 
or predict the chemical concentration in physical media such as surface water, groundwater, 
(indoor and outdoor) air, soils, sediments or surfaces. In the specific case of persistent 
pollutants that can move over long distances, long-range transport models are needed to 
evaluate the transfer of chemicals to remote regions. Fate models are essentially based on 
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biodegradation and partitioning properties of chemicals that govern their distribution among 
physical media. Second, bioaccumulation, and eventually bioconcentration are used to 
estimate the internal concentration in biological media that form part of the food chain. Third, 
for human exposure assessment, scenarios are constructed to estimate the potential exposure 
via ingestion, inhalation and dermal contact for chemicals present in the workplace or in the 
environment. This evaluation involves assumptions related to human behaviour, in particular 
the diet. Finally, once in the body, the chemical is subject to pharmaco-kinetic processes that 
govern its distribution in organs and tissues, its metabolism and elimination. The integration 
of all steps cannot be achieved without the support of mathematical models, able to deal with 
different space and time scales.  
With an ultimate goal of linking hazard and exposure assessment, the last step relative 
to the prediction of concentration in the body, in particular at the level of target organs or 
tissues, is crucial. At this step, all routes of exposure should be considered simultaneously, 
because the sum of internal doses from the different routes may not actually account for this 
multi-route exposure because of non-linear phenomena (saturation of liver metabolism, for 
instance). With regard to the internal concentration prediction, threshold levels at organ or 
tissue level (i.e. tolerable concentrations in target organs and tissues) should be available. At 
the moment, they are available only for few chemicals. However, with the progress in 
mechanistic toxicology, as well as the development of biomonitoring programmes, it can be 
expected that ‘equivalent biomonitoring reference Doses’ will be defined in the future. Some 
approaches based on reverse pharmacokinetic modeling are thus developed to calculate 
chemical- and tissue-specific concentration thresholds (or ‘biomonitoring equivalents’) for a 
wider range of chemicals (e.g. Hays et al, 2007; http://www.biomonitoringequivalents.net; 
http://www.umweltbundesamt.de/gesundheit-e/monitor/index.htm). Beyond the estimation of 
daily intakes provided by some existing models, the determination of internal effective 
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concentrations, i.e. in the target tissues where toxic effects arise, will be required in the future 
to comprehensively assess ‘exposure’ and to characterize accurately the link between the 
intake from the environment and health effects. However, we are not aware of any currently 
available modeling tool that incorporates fate and bioaccumulation models with 
pharmacokinetic models in a unique modeling system. Such integration would be useful for 
anticipating the future frontier between exposure and hazard assessment that will result from 
progress in mechanistic pharmacokinetics and biomonitoring programs. 
 
3.2. Data for exposure modeling 
 
Given the large spectrum of components involved in exposure assessment, as shown in 
Figure 2, no systematic recommendation can be made for survey/surveillance/monitoring 
programs. Exposure can indeed be (partly) assessed by using information from any or all of 
the steps defined in the full-chain assessment system, and by merging monitoring and 
modeled data. However, the main difficulty that exposure modelers face for validating their 
models is the absence of databases gathering monitoring data on the complete chain of 
assessment (i.e. data for environmental media, in food products, on population behaviour and 
on biomonitoring). Assessing how accurately mathematical models represent the real world, 
i.e. the complexity of environmental or human systems, is thus difficult to conduct because 
empirical data are seldom consistent regarding space and time and because key input data are 
often lacking. This absence of integrated databases can result from historical or management 
reasons since environmental, socio-economic (e.g. diet composition), biomonitoring and 
health status follow-up are generally not managed by the same institutions. Actually, data 
allowing a better exploitation of exposure models sometimes exist, but not always in a format 
allowing them to be readily collected in a homogenous form. Another way to better exploit 
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monitoring data would be to merge such data, even if sporadically available, with modelling 
results and/or expert judgement through e.g. Bayesian techniques. Exposure modelling 
results, eventually in conjunction with other existing knowledge such as gained from expert 
judgement, can form prior estimates of exposure. The prior distribution of exposure is updated 
using the measured concentrations (from historical measurements) and its associated variance 
to obtain the posterior probability distribution. Such approaches were commonly used in 
occupational exposure assessment where prior expert judgments about workers exposure are 
merged with exposure data, but they were rarely used in environmental exposure modeling 
(Tielemans et al., 2007; Ramachandran, 2008; Sottas et al., 2009). 
 
 
3.3. Uncertainty, standardisation and validation in Exposure modeling 
 
Integrated exposure assessment has to deal with different kinds of data (measured or 
predicted), different models for different compartments and more or less relevant descriptions 
of physico-chemical phenomena (transport, biodegradation, distribution). Uncertainty 
assessment is thus even more challenging in integrated exposure assessment than in integrated 
hazard assessment. Integrated exposure assessment relies on increasingly complex scenarios 
and models and involves interdisciplinary integration (e.g. as shown in Figure 2, from 
atmospheric long-range modeling to pharmacokinetic modeling). With this, the concept of 
uncertainty can be more ambiguous because it incorporates many different languages, goals 
and methodologies. It is therefore a major challenge to make the uncertainty concept more 
systematic, comprehensive, shared and understandable (Briggs, 2009). In order to overcome 
this challenge and to facilitate a transparent evaluation of uncertainty, a comprehensive, 
harmonized and structured list of criteria needs to be defined for the different components of 
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uncertainty. For example, the typology of uncertainty associated with exposure assessment 
could be classified as scenario uncertainty, model uncertainty, parametric uncertainty and 
measurement uncertainty. Some attempts were undertaken to better classify the components 
of uncertainty (HEIMSTA, 2009) and to define a tiered approach for qualitative and 
quantitative uncertainty in exposure assessment (WHO, 2008). These first attempts should 
however be followed by the construction of operational tools for identifying the sources of 
uncertainty in a more transparent and systematic way for improving further visualization and 
communication.  
In the same way as for ‘uncertainty’, the terms ‘standardisation’ and ‘validation’ can 
distinguish different aspects in exposure modeling and exposure assessment in general: (i) 
field validation (i.e. comparison between predicted and monitored data). Given the 
complexity of exposure pathways, validation is generally possible only on sub-models, but 
not on the complete aggregated full-chain described in Figure 2; (ii) benchmarking exercises 
(i.e. blind comparison of models on common scenarios); (iii) numerical validation (i.e. 
adequacy between user guide and software, verification of numerical schemes); (iv) 
documentation and transparency of tools; (v) relevance to the aim (e.g. spatial and temporal 
required resolution, steady-state vs dynamic scenario, analytical vs numerical solutions, 
mechanistic vs megression approach, deterministic vs probabilistic approach, etc).  
 
4. Integrated risk assessment of chemical mixtures 
 
The 2001 WHO report on Integrated Risk Assessment mentioned risks from exposure of 
humans and the environment to multiple agents via multiple routes as an important aspect. 
However, details of the application of the IRA concept to chemical mixtures were not worked 
out. In comparison to conventional single substance assessments, the assessment of the joint 
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toxicity of chemicals co-occurring in an exposure scenario may already be seen as an 
ambitious integrative step in itself. Beyond that, however, the basic idea of IRA, i.e. the 
integration of human risk assessment (HRA) and environmental risk assessment (ERA) in a 
single process, could also be extended from single chemicals to mixtures of chemicals. With 
this aim, the scope for integration may encompass four specific aspects: (i) the use of a 
common methodology for HRA and ERA of chemical mixtures, (ii) the use of a common 
strategy for  bridging gaps in single substance data sets that are needed for modeling human 
and environmental mixture toxicity, (iii) the identification of groups of substances with a 
common mode of action, so-called cumulative assessment groups (CAG), that are relevant in 
both humans and wildlife species, and (iv) the identification of common situations of joint 
exposure to multiple chemicals and the actual co-performance of HRA and ERA for such 
situations. 
Two different types of approaches are used for mixture toxicity assessments: the so-called 
“whole mixture approach” (WMA) and the “component-based approaches” (CBA) (see 
Kortenkamp et al., 2009 for an overview). The WMA means that the mixture of concern is 
experimentally tested just like a single substance. The CBA means that the expected toxicity 
of a mixture is calculated on the basis of toxicity data for individual mixture components by 
applying appropriate models of joint action. Whole mixture testing necessarily yields results 
that are specific for the actually tested mixture and endpoint. Extrapolations to similar 
mixtures and/or endpoints may be possible only under special circumstances. CBAs make use 
of generic mixture toxicity concepts that can be applied to any combination of chemicals for 
which single substance data are available for the endpoint of concern. Therefore, CBAs lend 
themselves to the development of an integrated approach, both in terms of a common 
methodology for calculating predictions of mixture toxicity and the use of a common strategy 
for bridging gaps in experimental single substance toxicity data.  
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Methods and models used for CBAs are essentially all based on one of only two different 
“non-interaction” concepts, or a combination of both: “concentration (or dose) addition” (CA) 
and “independent action” (IA) (also called “response addition”). CA assumes that mixture 
components have a similar mode of action. IA assumes that mixture components contribute to 
a common endpoint via dissimilar and fully independent chains of reactions. CA implies that 
concentrations (or doses) of substances below individual thresholds (zero effect levels) may 
still contribute to the overall toxicity of a mixture, while IA does not. CA and IA are well 
established concepts in both human and environmental mixture toxicology and have even 
been discussed in the context of epidemiological health risk assessments (Boedeker and 
Backhaus, 2010). Recently, the European Commission’s Scientific Committees proposed a 
tiered approach for mixture risk assessment that makes use of these concepts and that is 
intended to be applicable for both HRA and ERA of chemical mixtures (EC, 2011).  
Despite these methodological commonalities, however, there is a controversial issue where 
the opinions about the appropriate regulatory use of CBAs clearly differ between experts from 
the human and the environmental arena. This refers to the assessment of the toxicity of multi-
component mixtures of dissimilarly acting chemicals at low doses or concentrations, whereby 
“low” denotes levels that are considered to be regulatory acceptable for individual chemicals, 
such as “acceptable daily intake values” (ADI) or “derived no effect levels” (DNEL) for 
humans, and “predicted no effect concentrations” (PNEC) for organisms in the environment. 
As a recent communication from the European Commission points out, the Scientific 
Committees concluded that in relation to human health the level of concern about such 
mixture “should be assumed to be negligible”, while in relation to ecological effects, such 
mixtures should be “considered as a possible concern” (EC, 2012). 
Two of the various reasons for this dichotomy are the different types of endpoints and the 
different protection goals of ERA and HRA. ERA aims to protect populations of millions of 
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different species and considers apical endpoints such as mortality or population growth that 
may be affected by a multitude of chemicals with diverse modes of action. To this end, the 
general assumption of CA is widely accepted as a cautious and not vastly over-protective first 
tier approach (ECETOC, 2011; Backhaus and Faust, 2012). HRA, in contrast, seeks to protect 
individual humans from adverse health outcomes that may be caused by specific types of 
chemicals with specific modes of action only, such as certain forms of cancer for instance. As 
a consequence, grouping of chemicals into appropriate CAGs is considered to be an important 
step for HRA of chemical mixtures, but it is often hampered by missing knowledge about the 
modes of action of environmentally relevant chemicals. Integrated approaches such as the 
AOP concept outlined in section 2.4 may play a key role for advancements in the field of 
grouping chemicals for human mixture risk assessments. 
Toxicokinetic or toxicodynamic interactions of mixture components may result in significant 
deviations of the actual mixture toxicity from predictions based on the non-interaction 
concepts of CA and IA. Synergistic effects that are much stronger than expectable are 
obviously a rare event (Kortenkamp et al., 2009; Boobis et al., 2011) but they give reasons for 
particular regulatory concern. The search for tools that would allow identification of 
synergistic substance combinations in a systematic way is on-going and there is great hope 
that this could become achievable in the future by means of toxicogenomic approaches 
(Altenburger et al., 2012). Currently, however, the potential for interactions can only be 
evaluated on a case-by-case basis. To this end, the so-called “binary weight of evidence” 
approach (BINWOE) has been developed for the purpose of human health hazard assessments 
(Pohl et al., 2009). This is a resource intensive semi-quantitative assessment tool, which has 
been used by the US Agency for Toxic Substances and Disease Registry (ATSDR) for 
characterizing the likelihood of interactions in certain priority mixtures 
(www.atsdr.cdc.gov/interactionprofiles/index.asp). For the environmental hazard assessment 
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of mixtures, analogous approaches are lacking at the moment. An integrated risk assessment 
approach may trigger corresponding advancements. 
Application of physiologically based pharmacokinetic/pharmakodynamic modelling 
(PBPK/PD) is an advanced approach to chemical mixture toxicology (e.g. Krishnan et al., 
1994; Price and Krishnan, 2011). PBPK/PD models are highly specific for a particular animal 
and require detailed knowledge of its physiology, such as for example the exposed skin 
surface or the alveolar ventilation rate. Specific data for the relevant mixture components are 
needed, such as blood/air, blood/tissue partition coefficients and metabolic rate constants. 
Krishnan et al. (1994) list some 45 parameters that build up these models. In view of these 
huge data demands, actual application of this approach has been confined to studies of 
mixtures with only a few compounds in a few selected animal test systems (Krishnan et al., 
1994; Verhaar et al., 1997). In principle, the methodology is useful for both HRA and ERA of 
mixtures. In practice, however, applicability in the field of ERA is strongly limited by 
insufficient knowledge about the detailed physiology of most of the many different organisms 
in an ecosystem. 
Similar situations of co-exposure of both humans and environmental organisms to multiple 
chemicals may provide starting points for performing integrated mixture hazard and risk 
assessments. Surface waters, for instance, may contain a complex cocktail of contaminants to 
which aquatic organisms are directly exposed, while exposure of humans to a similar or 
different mixture of the same components could occur via the consumption of drinking water 
or fish. As part of the development of a WHO/IPCS framework for mixture risk assessments, 
a case study was performed on a hypothetical mixture of 10 contaminants that have been 
detected in US surface water monitoring programs (Meek et al., 2011). The study was 
confined to the cumulative risk for humans from the use of surface water as drinking water. 
However, it is imaginable that such a study design could be extended from hypothetical to 
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real mixtures and from an isolated HRA to an integrated assessment of the risks to both 
humans and aquatic organisms. Such types of in-depth case studies could help to clarify in 
detail, where human and ecological assessments of cumulative risks can really benefit from 
each other and where integration may only produce a counterproductive increase in 
complexity, time and costs. 
 
5. Integrating RA and Socio-Economic Analysis (SEA) 
 
5.1. Socio-economic assessment and its status in EU Regulation 
 
Socio-economic assessment - or analysis - (SEA) can be regarded as a form of 
regulatory impact assessment used in the management of environmental and health risks. 
Regulatory impact analysis is used by public authorities “to balance the potential benefits and 
costs of action or lack of action”, as mentioned in the EU treaty (Foundation for EU 
Democracy, 2009). The conceptual framework for environmental policy assessment is, as 
clearly expressed in the case of the EU by the above excerpt of the treaty, welfare economics 
and cost-benefit analysis. Several European directives or regulations (e.g. Water Framework 
Directive, Industrial Emissions Directive, REACH regulation) explicitly refer to cost-benefit 
analysis or SEA (ECHA, 2008).  
The ambition of SEA in the context of chemicals management is to get a rational, 
balanced and holistic view of advantages and drawbacks of the continued use or withdrawal 
of chemicals that are on the market. Basically, SEA consists of an inventory and an 
assessment of all positive (benefits from its use) and negative impacts (originating in health 
and environmental risks) of the chemical, and of its alternatives, and then compares the 
chemical and the alternatives in terms of the overall social value (benefits minus costs) that 
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they bring to society. SEA also offers the ability to handle chemical risks management in a 
framework that is also capable of being used to study other risks (including other 
environmental, health or technological risk issues), therefore improving the consistency of 
policymaking. 
 
5.2. How risk assessment can be supported by socio-economic assessment? 
The SEA framework is formulated in terms of outcomes that are understandable and 
matter citizens (good health, quality of life, costs). It thus helps in expressing and therefore 
communicating on risks and risk policy, in a way that is meaningful to non-specialized 
decision makers and to the public. SEA is also capable of providing integrated views of 
impacts across human health and the environment, thus promoting what could be called an 
“integration of outputs”. Given that most of the EU regulation, either explicitly or in its 
practical implementation, still considers human health and ecosystems issues separately, 
better policy making can be expected when progress is made in that direction. Furthermore, 
SEA can work with RA on the improvement of models and methods in RA : since SEA is 
working on use and release of chemicals in the economy (use pattern scenarios) there could be 
collaboration on setting industrial or domestic use patterns and consumers or workers 
behaviour, by cooperation between social scientists and exposure assessors (e.g. hygienists). 
In the case of REACH, the two expert committees of the European Chemicals Agency 
respectively working on RA and SEA are actually working together to produce common 
opinion documents on the managements of specific chemicals for the Agency.  
There are, however, many challenges to overcome before SEA can actually augment 
RA. First, SEA itself faces methodological and data challenges that are in some cases unlikely 
to be resolved in the short term (e.g. how to derive accurate costs of reducing risks in 
situations of asymmetric information between regulators and regulated, or how to derive the 
 28 
value of reducing risks associated with uncertain impacts on ecosystems ) SEA outputs need 
to be given within acceptable ranges of uncertainty and scientific consensus to deliver useful 
information for integrated RA and risk management. Second, a real and fruitful integration 
would only occur if the outcome of RA provides a relevant input for SEA. SEA requires that 
the assessment of effects such as reprotoxicity or neurotoxicity would be as much as possible 
related to endpoints that can be appraised in an economic framework, such as fertility or loss 
of IQ points. Several other examples of the difficulties to harmonize RA and SEA needs can 
be given (see (SCHER/SCENIHR/SCCS, 2011)): “risk characterisation ratios” cannot as such 
be assessed in socio-economic terms; RA is often looking at worst cases, in order to derive 
protective risk estimates for individuals or selected animal species, whereas SEA is often 
concerned with looking at central tendency estimates of risk and their distribution among the 
whole population ; SEA considers not only the substance under investigation but also 
substitute substances that could be used as less harmful surrogates, which means that RA for 
these substances would also be required. More generally, SEA promotes working on 
groupings that would be meaningful in a socio-economic viewpoint, in addition to physico-
chemical or modes of action considerations, by looking at groups that are consistent in terms 
of societal issues and responses. 
It is thus crucial to connect the respective indicators in RA and SEA in order to share 
the terminologies or to build “intermediate indicators” between those used by RA (e.g. cancer 
risk indicators) and SEA (e.g. socio-economic impacts of cancers). Work has been initiated 
recently (WCA Environment, 2011; Verhoeven J.K., et al., 2012) to explore how to use 
concepts or tools such as LCA (life-cycle assessment) and SSD (species sensitivities 
distributions) to translate environmental risk assessments (ERA) results into useful inputs for 
SEA.  
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In this context, however, producing economic estimates of the damage costs to health 
and the environment still raises questions that go beyond strict SEA disciplinary perspectives 
and practices. Insights from other disciplines are necessary in order to ensure that SEA 
contributes to integrated RA with more credibility and acceptance (Gezondheidsraad, 2008).  
  
5.3. Addressing issues related to social impact 
 
Beyond the capacity to produce economic estimates of the costs to health and 
environment following a risk assessment process, the challenges to contribute to a sustainable 
societal model involve also addressing issues related to social impact. 
Indicators from RA with sociological relevance would help SEA to improve the 
relevance of RA. The OECD identifies in the OECD Better Life Index 11 (OECD, 2012) the 
following topics as essential in the areas of material living conditions and quality of life: 
housing, income, jobs, community, education, environment, civic engagement, health, life 
satisfaction, safety and work-life balance. Relevant aspects could be captured in indicators 
which reflect inter alia elements specific to value creation for the society as whole, like: 
improving living conditions; creating opportunities for certain categories of people, in terms 
of economic growth and jobs; developments in terms of technology and knowledge; 
maintenance or improvement of certain ecosystem services; health benefits; etc. When 
focusing on chemicals, more detailed and precise indicators could be identified, like in the 
case of pesticides or fertilisers, their contribution to aspects of food security, poverty, and 
malnutrition alleviation and eradication. Food security indicators should cover aspects related 
to availability (including energy and protein supply), physical access to food, and economic 
access and utilization (FAO, 2012). With reference to environmental assessment, indicators 
can be derived to feed into the evaluation of the impact on ecosystem services. The concept of 
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the ecosystem services can be addressed using the four categories of services identified by the 
Millennium Ecosystem Assessment (Millennium Ecosystem Assessment, 2005): provisioning 
services, regulating services, habitat and supporting services and cultural services. Some of 
the impacts on ecosystem services might already be captured in the IRA through the 
protection goals assumed in the assessment process (i.e. air quality; quality of water or 
protecting biodiversity) while others remain outside the assessment process generated by the 
regulatory framework (i.e. provision of food and raw materials; carbon sequestration and 
storage; impact on climate change; soil fertility; recreation and mental and physical heath; 
aesthetic appreciation; cultural aspects; etc.). The evaluation of these impacts would help 
decision makers derive a more informed decision as well as considering the costs and benefits 
for society of their decision and establishing the appropriate trade-offs. 
A relevant contribution to RA by sociological aspects could also be addressing the gap 
between risk assessment and risk perception, social scientists being able to study and reveal 
risk and benefits perceptions in the society and in certain cases using certain methodologies to 
evaluate the changes in the perceptions on specific risks (Dreyer et al., 2010). Hence, SEAs 
would not only rely on “scientific” risk estimates from RA but also be able to predict societal 
perception of risks, thereby enriching the economic concepts of value, and supporting risk 
managers to better communicate on risks and mitigation measures. Extensive experience and 
scientific literature exist in this area, showing the importance of perceptions dimensions that 
are not reducible to economic value formation (see for instance Gupta et al., 2012 and 
Satterfield et al., 2009 for a discussion in the case of nanomaterials). 
When social values are to be studied, the point of view from political science 
perspectives could be clarified with the involvement of social scientists as well as ethicists 
(for instance, consideration of animal testing issues). At this stage, foresight on various 
changes to policy frameworks required in the future and impacted by the IRA and SEA 
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process would definitely provide useful information.  However, it is important to remember 
that, even when augmented with the recourse to those many expert categories, SEA should 
not be used as a substitution to political decision on risk management priorities in a society. 
 
6. Conclusions and future challenges 
 
This paper describes the scope and prospects of the integrated assessment and of 
including socio-economic analysis in this risk assessment. A number of recommendations for 
the next research steps can be derived from this analysis. Integrated hazard assessment would 
benefit from developments and validations of ITS able to synthesize information from test and 
non-test methods, with or without extrapolation between species or levels of biological 
organizations. To improve the use and the relevance of these ITS, data extrapolation methods 
are available, based on modeling (PBPK models for instance) and we should consider modes 
of action to support the integration of information across human and environmental endpoints. 
The first step will be to assess whether existing methods and WoE schemes can address this 
assessment of mode of action adequately, or whether additional research is needed. 
Exposure assessment would require new developments to relate the exposure 
concentrations for the different routes of exposure, the measurements from biomonitoring and 
relevant internal concentrations, and by linking with hazard assessment. Again, generic PBPK 
models would allow the goal to be achieved.  
Initiatives should also be started, that aim at a better exchange between RA and SEA 
in order to better inform about risk management options available following the risk 
assessment. 
Clear opportunities for demonstrating the value of integration have been identified for 
mixture RA, such as the use of a consistent methodology for both human RAs and 
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environmental RAs of chemical mixtures, based on generic approaches and common 
principles, as well as the consistent use of methodologies for extrapolating between different 
individual chemicals and different endpoints in order to bridge gaps in single substance data 
sets. 
The HEROIC project has been designed to help identify and answer the needs for 
IRA. It will contribute to the practical implementation of IRA by building a central 
knowledge platform to create awareness for and facilitate access to human and environmental 
RA data; by promoting the use of non-test methods to extrapolate data or generate new ones; 
by considering the relevance of key concepts such as MOA and AOP to support the use of 
environmental toxicity data as a substitute for human/animal toxicity data, and vice versa; by 
promoting a dialogue between RA and SEA. HEROIC works in a more favourable 
environment compared to previous initiatives since the accessibility of new data sets 
generated under REACH will facilitate the cross-comparability of human and environmental 
risk assessment data. Since previous case studies trying to highlight the potential benefits of 
IRA have not had a significant impact, it is of importance that real-life case studies will be 
developed to fully demonstrate the potential and relevance of IRA, in particular with regard to 
cost-benefits analysis,  and maximize its use in future risk assessment procedures at the 
regulatory level. 
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Figure 1. Schematic representation of a sequence of steps representing an adverse outcome 
pathway (AOP) 
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Figure 2 – Successive stages involved in Exposure assessment 
 
